Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: Are short-term treatment outcomes for alcohol dependence improved?

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 5, 2002, Pages 622-628

  Feeney, Gerald F X ^a   Young, Ross Mc D ^a   Connor, Jason P ^a   Tucker, Jane ^a   McPherson, Annie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acamprosate; Alcohol dependence; CBT; Treatment

Indexed keywords

ACAMPROSATE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; AUSTRALIA; BEHAVIOR THERAPY; BODY WEIGHT; COGNITIVE THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; OUTPATIENT CARE; PHARMACEUTICAL CARE; PRESCRIPTION; PROGNOSIS; PSYCHOTHERAPY; REHABILITATION MEDICINE; RELAPSE; TABLET; TREATMENT OUTCOME;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; AMBULATORY CARE; COGNITIVE THERAPY; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TAURINE;

EID: 0036796173     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2002.01019.x     Document Type: Article

References (44)

1. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. a controlled study. Archives of General Psychiatry 1992; 49:881-887.
2. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment outcomes. Journal of Studies on Alcohol 1997; 58:7-29.
3. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: project MATCH three year drinking outcomes. Alcoholism: Clinical and Experimental Research 1998; 22:1300-1311.
4. Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92:381-395.
5. Cornelius JR, Salloum IM, Ehler JG et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled Trial. Archives of General Psychiatry 1997; 54:700-705.
6. Kranzler HR, Burleson JA, Korner P et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 1995; 152:391-397.
7. Johnson BA, Roache JD, Javors MA et al. Ondansetron for reduction among biologically predisposed alcoholic patients: a randomised controlled trial. Journal of the American Medical Association 2000; 284:963-971.
8. Malec E, Malec T, Gagne MA et al. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcoholism: Clinical and Experimental Research 1996; 20:307-312.
9. Mueller TI, Stout RL, Rudden S et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 1997; 21:86-92.
10. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992; 49:876-880.
11. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioural therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. American Journal of Psychiatry 1999; 156:1758-1764.
12. Feeney GF, Young RMcD, Connor JP, Tucker J, McPherson A. Outpatient Cognitive Behavioural Therapy Program (CBT) for alcohol dependence. Impact of naltrexone on outcome. Australian and New Zealand Journal of Psychiatry 2001; 35:443-448.
13. Hunt WA. Neuroscience research: how has it contributed to our understanding of alcohol abuse and alcoholism? A review. Alcoholism: Clinical and Experimental Research 1993; 17:1055-1065.
14. Mason BJ, Owenby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo controlled trials. CNS Spectrums 2000; 5:58-69.
15. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90:1179-1188.
16. Potgieter A. Overview of the European acamprosate data. 4th European symposium on Acamprosate. Oxford Scientific Series 2001; 2:16-19.
17. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol and Alcoholism 2000; 35:478-492.
18. Lhuintre JP, Moore ND, Tran G et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and Alcoholism 1990; 25:613-622.
19. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism 1995; 30:239-247.
20. Whitworth AB, Fischer F, Lesch OM et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347:1438-1442.
21. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 1996; 53:673-680.
22. Pelc I, Verbank P, Le Bon O, Gavnovlic M, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 1997; 171:73-77.
23. Poldrugo F. Acamprosate treatment in a long-term community based alcohol rehabilitation programme. Addiction 1997; 92:1537-1546.
24. Barrias JA, Chabac S, Ferreira L et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 1997; 18:149-160.
25. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. A combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcoholism: Clinical and Experimental Research 1998; 22:573-579.
26. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol and Alcoholism 2000; 35:202-209.
27. Chick J, Howlett M, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol and Alcoholism 2000; 35:176-187.
28. Ansoms C, Deckers F, Lehert P, Pelc I, Potgieter A. An open study with acamprosate in Belgium and Luxemburg: results on sociodempgraphics, supportive treatment and outcome. European Addiction Research 2000; 6:132-140.
29. Bandura A. Social foundations of thought and action. New Jersey: Prentice Hall, 1986.
30. Marlatt GA, Gordon JR. Relapse prevention: maintenance strategies in the treatment of addictive behaviours. New York: Guilford, 1985.
31. Maisto SA, Carey KB, Bradizza CL. Social learning theory. In: Leonard KE, Blane HT, eds. Psychological theories of drinking and alcoholism. New York: Guilford, 1999; 106-153.
32. Morgenstern J, Longbaugh R. Cognitive-behavioural treatment for alcohol dependence: a review of evidence for its hypothesised mechanism of action. Addiction 2000; 95:1475-1490.
33. Allan C, Smith I, Mellin M. Detoxification from alcohol. A comparison of home detoxification and hospital-based day patient care. Alcohol and Alcoholism 2000; 35:66-69.
34. Pokorny AD, Miller BA, Kaplan HB. The brief MAST: a shortened version of the Michigan Alcoholism Screening Test. American Journal of Psychiatry 1972; 129:342-345.
35. Carter SK. Clinical considerations in the design of clinical trials. Cancer Treatment Reports 1980; 64:367-371.
36. Fong IW, Ho J, Toy C, Lo B, Fong MW. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma. Case-control and historical cohort studies. Clinical Infectious Diseases 2000; 30:757-761.
37. Ellison GW, Mickey MR, Myers LW. Alternatives to randomised clinical trials. Neurology 1988; 38 (Suppl. 2):73-75.
38. Bhansali MS, Patil PK, Badwe RA, Havalda R, Desai PB. Historical control bias: adjuvant chemotherapy in esophageal cancer. Diseases of the Esophagus 1997; 10:51-54.
39. Babor TF, Steinberg K, Anton R, Del Boca F. Talk is cheap: measuring drinking outcomes in clinical trials. Journal of Studies on Alcohol 2000; 61:55-63.
40. Hunt WA, Barnett W, Branch LG. Relapse rates in addiction programs. Journal of Clinical Psychology 1971; 27:455-456.
41. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: treatment main effects on drinking during treatment. Journal of Studies on Alcohol 1998; 59:631-639.
42. Schuckit MA, Tipp JE, Smith TL, Buchilz KK. Periods of abstinence following the onset of alcohol dependence in 1, 853 men and women. Journal of Studies on Alcohol 1997; 58:581-589.
43. Namkoong K, Farren CF, O'Connor PG, O'Malley SS. Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications. Journal of Clinical Psychiatry 1999; 60:449-453.
44. Feeney GFX, Connor JP, Young McD, Tucker J, Czajkowski F. Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme. Journal of Clinical Pharmacy and Therapeutics 2001; 26:73-79.